HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies.

AbstractBACKGROUND:
Phosphatase and tensin homolog (PTEN) hamartoma tumor syndrome (PHTS) is caused by germ line mutations in the PTEN gene. Symptoms include cancer predisposition, immune deviations, and lipomas/lipomatosis. No causal standard therapy is available. We describe a therapeutic attempt with the mammalian target of rapamycin (mTOR) inhibitor sirolimus for a PHTS patient suffering from thymus hyperplasia and lipomatosis. We furthermore assessed the in vitro effects of sirolimus and other inhibitors on lipoma cells of the patient.
METHODS:
The patient underwent clinical and blood examinations and whole-body magnetic resonance imaging to assess tumor sizes. Lipoma cells of the patient were incubated with inhibitors of the phosphoinositide-3-kinase (PI3K)/AKT/mTOR signaling pathway to analyze the effects on proliferation, adipocyte differentiation, and survival in vitro.
RESULTS:
Sirolimus treatment improved somatic growth and reduced thymus volume. These effects diminished over the treatment period of 19 mo. Sirolimus decreased lipoma cell proliferation and adipocyte differentiation in vitro but did not cause apoptosis. PI3K and AKT inhibitors induced apoptosis significantly.
CONCLUSION:
Sirolimus treatment led to an improvement of the patient's clinical status and a transient reduction of the thymus. Our in vitro findings point to PI3K and AKT inhibitors as potential treatment options for patients with severe forms of PHTS.
AuthorsGordian L Schmid, Franziska Kässner, Holm H Uhlig, Antje Körner, Jürgen Kratzsch, Norman Händel, Fred-P Zepp, Frank Kowalzik, Andreas Laner, Sven Starke, Franziska K Wilhelm, Susanne Schuster, Adrian Viehweger, Wolfgang Hirsch, Wieland Kiess, Antje Garten
JournalPediatric research (Pediatr Res) Vol. 75 Issue 4 Pg. 527-34 (Apr 2014) ISSN: 1530-0447 [Electronic] United States
PMID24366516 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Sirolimus
Topics
  • Child, Preschool
  • Hamartoma Syndrome, Multiple (drug therapy, genetics)
  • Humans
  • In Vitro Techniques
  • Infant
  • Infant, Newborn
  • PTEN Phosphohydrolase (genetics)
  • Sirolimus (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: